Subscribe To
MYCOF / Mydecine Innovations Group set to raise up to $4M in previously announced overnight public offering
MYCOF News
By Proactive Investors
May 27, 2022
Mydecine Innovations closes 'best efforts' overnight marketed offering for aggregate gross proceeds of $2,814,199.50
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) said it has closed its previously announced 'best efforts' overnight marketed offering of units f more_horizontal
By Proactive Investors
May 19, 2022
Mydecine Innovations Group set to raise up to $4M in previously announced overnight public offering
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) has announced the size of its previously announced overnight public offering, saying it will issu more_horizontal
By Proactive Investors
April 1, 2022
Mydecine ends FY2021 with C$1.5M in cash to help propel mental health treatment initiatives in 2022
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) ended 2021 with C$1.5 million in cash and decribed the just-ended financial year as one in which more_horizontal
By Proactive Investors
March 24, 2022
Mydecine wins conditional approval from Institutional Review Board for Phase 2b smoking cessation study
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO). said it has received conditional approval from the Institutional Review Board (IRB) for its mult more_horizontal
By GlobeNewsWire
March 3, 2022
Mydecine To Attend March Investor Conferences
Learn more about Mydecine's clinical trials and drug development strategy by scheduling a meeting with management Learn more about Mydecine's clinical more_horizontal
By GlobeNewsWire
March 3, 2022
Mydecine To Attend March Investor Conferences
Learn more about Mydecine's clinical trials and drug development strategy by scheduling a meeting with management Learn more about Mydecine's clinical more_horizontal
By GlobeNewsWire
March 3, 2022
Mydecine To Attend March Investor Conferences
Learn more about Mydecine's clinical trials and drug development strategy by scheduling a meeting with management Learn more about Mydecine's clinical more_horizontal
By Proactive Investors
February 16, 2022
Mydecine Innovations announces inclusion of molecule with improved heart-safe microdose properties in its family of psilocin analogs
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) has announced the inclusion of a novel molecule with potentially heart-safe microdose enabling pr more_horizontal